NCT06608641 - Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients | Biotech Hunter

Enrollment

490

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Bipolar 1 Disorder

Interventions

DRUG

Endoxifen enteric-coated tablet (8 mg)

Patients will continue treatment with their initial randomized medication for 3 weeks

DRUG

Placebo Tablets

Patients will be treated with Endoxifen Placebo Tablets for 21 days

Trial Locations (12)

Accelerated Clinical Trials, LLC, Peachtree Corners

Accelerated Clinical Trials, LLC, Norcross

Accelerated Clinical Trials, LLC, East Point

Innovative Clinical Research, Inc., Miami Lakes

Medical Research of Westchester, Inc., Miami

South Florida Research Phase I-IV, Inc., Miami Springs

Sunshine Medical Research Studies Inc., Miami

Santos Research Center, CORP, Tampa

Precise Research Centers, Flowood

NRC Research Institute, Los Angeles

Synexus, Cerritos

NRC Research Institute, Orange